FleishmanHillard, a privately owned company headquartered in the US, was founded in 1946 and employs approximately 2700 individuals. The company operates primarily in the realm of Public Relations and Communications Services, functioning as a communications agency.
On September 21, 2026, a report stemming from a July 9 webinar hosted by communications consultancy FleishmanHillard highlighted that 12% of US adults have tried a GLP-1 drug. The webinar further projected that approximately 25% of respondents expect to take these medications by 2026, with Gen Z showing the highest anticipated adoption at 37%. Earlier in September, FleishmanHillard appointed Bibi Hilton as UK chair of brand impact and EMEA managing director of brand. Hilton, who joined the agency on September 1, provides senior strategic counsel to clients and helps shape the direction of FleishmanHillard’s brand business in the UK and across EMEA.
Subscribe for full access to FleishmanHillard's products in full detail
Subscribe for full access to FleishmanHillard's revenue in full detail
Subscribe for full access to FleishmanHillard's products in full detail 
